早期FCR对比观察等待治疗Binet A期高危CLL的随机3期试验
中位观察55.6个月,FCR组无事件生存显著延长(中位未达到 vs 18.5个月,p<0.001),但总生存无显著获益(5年OS 82.9% vs 79.9%,p=0.864)。
要点
- 早期FCR可显著延长高危Binet A期CLL的无事件生存,但总生存无获益。
- FCR总缓解率92.7%,常见不良事件为血液学毒性和感染。
- 数据不支持改变高危早期CLL现行观察等待标准。
核心结论
- FCR可有效诱导Binet A期高危CLL缓解并延长无事件生存,但未显示总生存获益,不支持改变观察等待标准。
主要发现
- 早期FCR后总缓解率为92.7%。
- 常见不良事件为血液学毒性和感染,分别发生于61.0%和41.5%的患者。
- 中位观察55.6(0-99.2)个月,FCR组无事件生存显著长于观察等待组(中位未达到 vs 18.5个月,p<0.001)。
- 高危患者早期FCR无显著总生存获益(5年OS 82.9% vs 79.9%,p=0.864)。
关键数值与推荐
- 高危特征包括:淋巴细胞倍增时间<12个月、血清胸苷激酶>10 U/L、IGHV基因未突变、不良细胞遗传学(del(11q)/del(17p)/ trisomy 12)。
- 具有≥2项高危特征定义为高危CLL。
临床怎么用
- 对Binet A期高危CLL,早期FCR虽可延长无事件生存,但总生存无获益,不应常规替代观察等待。
- 治疗决策需权衡FCR的血液学毒性和感染风险。
局限性
- 中位观察55.6个月,总生存数据可能尚不成熟。
- 高危定义基于四项标志中≥2项,结论推广至其他高危定义需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with untreated-stage Binet A disease were enrolled as intent-to-treat population and assessed for four prognostic markers: lymphocyte doubling time <12 months, serum thymidine kinase >10 U/L, unmutated IGHV genes, and unfavorable cytogenetics (del(11q)/del(17p)/trisomy 12). Two hundred and one patients with ≥2 risk features were classified as high-risk CLL and 1:1 randomized to receive either immediate therapy with 6xFCR (Hi-FCR, 100 patients), or to be observed according to standard of care (Hi-W&W, 101 patients). The overall response rate after early FCR was 92.7%. Common adverse events were hematological toxicities and infections (61.0%/41.5% of patients, respectively). After median observation time of 55.6 (0-99.2) months, event-free survival was significantly prolonged in Hi-FCR compared with Hi-W&W patients (median not reached vs. 18.5 months, p < 0.001). There was no significant overall survival benefit for high-risk patients receiving early FCR therapy (5-year OS 82.9% in Hi-FCR vs. 79.9% in Hi-W&W, p = 0.864). In conclusion, although FCR is efficient to induce remissions in the Binet A high-risk CLL, our data do not provide evidence that alters the current standard of care "watch and wait" for these patients.
引用
- Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020. PMID: 32071431. doi:10.1038/s41375-020-0747-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。